title: High-risk HPV detection by Hybrid Capture and ploidy determination by a computer-assisted system in cervical biopsies.
abstract: OBJECTIVE
  To correlate high-risk HPV (hrHPV) detection by Hybrid Capture II (HC2) (Digene, Gaithersburg, Maryland, U.S.A.) with DNA content (ploidy) of cervical biopsies analyzed by a computer-assisted system.
  
  
  METHODS
  Cervical biopsies from 54 women examined at Leonor Mendes de Barros Hospital, São Paulo, as part of the Latin American Screening study during 2002--2003, were tested for hrHPV with HC2. All patients had been referred for colposcopic examination due to an abnormal cervical cytology. The final diagnosis included 30 cervicitis, 14 cervical intraepithelial neoplasia (CIN) 1, 5 CIN 2, 4 CIN 3 and 1 squamous cell carcinoma (SCC). Five-micrometer sections of each biopsy were stained with Feulgen-tionine and evaluated with the CAS 200 System (Becton Dickinson, U.S.A.), using the 3.0 software (version 8.1) of the DNA Quantitative Measurement Program (Becton Dickinson). Ploidy was evaluated from histograms obtained by analyzing atypical nuclei.
  
  
  RESULTS
  Of the 30 cervicitis cases, 28 (93.3%) were diploid, and hrHPV was detected in 8 (28.5%) of the cases. Two tetraploid cervicitis lesions were observed, 1 positive and 1 negative for hrHPV. Among the CIN 1 lesions, 8 (57.1%) were diploid and 6 (42.8%) aneuploid. Of the latter, 4 (66.6%) were negative and 2 (33.3%) positive for hrHPV. Of the 5 CIN 2 lesions, 2 were diploid, 2 aneuploid and 1 tetraploid; all were positive for hrHPV. All CIN 3 lesions and the SCC proved to be aneuploid and positive for hrHPV.
  
  
  CONCLUSIONS
  The data suggest that the majority of cervicitis and CIN 1 lesions are diploid and negativef or hrHPV. This is in sharp contrast to high grade CIN 2-3 lesions, all of which were positive for hrHPV in this study and also aneuploid, consistent with their progressive potential.
authors.affiliation: Instituto Adolfo Lutz, São Paulo, Brazil. shirata86@hotmail.com
authors.forename: Neuza Kasumi
authors.initials: NK
authors.lastname: Shirata
authors.forename: Luiz Marcelo Warneck
authors.initials: LM
authors.lastname: Espoladore
authors.forename: Adhemar Longatto
authors.initials: AL
authors.lastname: Filho
authors.forename: Janaína Erica
authors.initials: JE
authors.lastname: Pittoli
authors.forename: Celso
authors.initials: C
authors.lastname: di Loreto
authors.forename: Sonia Maria Miranda
authors.initials: SM
authors.lastname: Pereira
authors.forename: Marina Yoshie Sakamoto
authors.initials: MY
authors.lastname: Maeda
authors.forename: Maria Lúcia
authors.initials: ML
authors.lastname: Utagawa
authors.forename: Luciana
authors.initials: L
authors.lastname: da Silva Aguiar
authors.forename: Cecília
authors.initials: C
authors.lastname: Roteli-Martins
authors.forename: Edson G
authors.initials: EG
authors.lastname: Martinez
authors.forename: Kari
authors.initials: K
authors.lastname: Syrjänen
mesh_terms: D002294:Carcinoma, Squamous Cell; D002467:Cell Nucleus / Q000473:pathology; D002584:Cervix Uteri / Q000473:pathology*; D003936:Diagnosis, Computer-Assisted / Q000379:methods*; D003937:Diagnosis, Differential; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis*; D011003:Ploidies; D012306:Risk; D002575:Uterine Cervicitis / Q000175:diagnosis; D002578:Uterine Cervical Dysplasia